NTT DATA Research Reveals C-Suite Misalignment Over GenAI Adoption
17.6.2025 14:00:00 CEST | Business Wire | Press Release
NTT DATA, a global leader in digital business and technology services, today launched its new report, “The AI Security Balancing Act: From Risk to Innovation,” highlighting the opportunities and risks AI presents in cybersecurity. The findings show a misalignment among C-Suite leaders when it comes to business goals and operational readiness for GenAI deployment.
The report, which includes data from an NTT DATA survey of more than 2,300 senior GenAI decision makers,comprising 1,500 *C-Suite leaders across 34 countries, found that while CEOs and business leaders are committed to GenAI adoption, CISOs and operational leaders lack the necessary guidance, clarity and resources to fully address security risks and infrastructure challenges associated with deployment.
The C-Suite disconnect
Nearly all (99%) C-Suite executives are planning further GenAI investments over the next two years, with 67% of CEOs planning significant commitments.
In parallel, 95% of CIOs and CTOs report that GenAI has already driven, or will drive, greater cybersecurity investments, with organizations ranking improved security as one of the top three business benefits realized from GenAI deployment in the last 12 months.
Yet, even with this optimism, there is a notable disconnect between strategic ambitions and operational execution with nearly half of CISOs (45%) expressing negative sentiments toward GenAI adoption. More than half (54%) of CISOs say internal guidelines or policies on GenAI responsibility are unclear, yet only 20% of CEOs share the same concern – revealing a stark gap in executive alignment.
Despite feeling cautious about the deployment of GenAI, security teams still acknowledge its business value. In fact, 81% of senior IT security leaders with negative sentiments still agree GenAI will boost efficiency and impact the bottom-line.
Organizational operations not ready for GenAI
NTT DATA’s research further reveals a critical gap between leadership’s vision and the capabilities of their teams. While 97% of CISOs identify as decision makers on GenAI, 69% acknowledge that their teams lack the necessary skills to work with the technology.
In addition, only 38% of CISOs say their GenAI and cybersecurity strategies are aligned compared to 51% of CEOs.
Adding to the complexity, 72% of organizations surveyed still lack a formal GenAI usage policy and just 24% of CISOs strongly agree that their organization has a robust framework for balancing risk with value creation.
Legacy tech limiting GenAI adoption
Beyond internal misalignment, 88% of security leaders said legacy infrastructure is greatly affecting business agility and GenAI readiness, with modernizing IoT, 5G and edge computing identified as essential for future progress.
To navigate these obstacles, 64% of CISOs are prioritizing co-innovation with strategic IT partners rather than relying on standalone AI solutions. Notably, security leaders #1 top criteria when assessing GenAI technology partners is end-to-end GenAI service offerings.
"As organizations accelerate GenAI adoption, cybersecurity must be embedded from the outset to reinforce resilience. While CEOs champion innovation, ensuring seamless collaboration between cybersecurity and business strategy is critical to mitigating emerging risks," said Sheetal Mehta, Senior Vice President and Global Head of Cybersecurity at NTT DATA, Inc. "A secure and scalable approach to GenAI requires proactive alignment, modern infrastructure and trusted co-innovation to protect enterprises from emerging threats while unlocking AI’s full potential."
"Collaboration is highly valued by line-of-business leaders in their relationships with CISOs. However, disconnects remain, with gaps between the organization's desired risk posture and its current cybersecurity capabilities,” said Craig Robinson, Research Vice President, Security Services at IDC. “While the use of GenAI clearly provides benefits to the enterprise, CISOs and Global Risk and Compliance leaders struggle to communicate the need for proper governance and guardrails, making alignment with business leaders essential for implementation."
Download the full report here, and visit our website to learn more about NTT DATA’s AI services for cybersecurity.
Methodology
The report is based on insights from 2,300 senior GenAI decision-makers across 34 countries. 68% of respondents were from the C-suite, including CEOs, CISOs, CIOs, CTOs, CDOs, COOs, CCOs, CFOs, CHROs, and CSEs. 27% held Vice President, Head of, or Director-level roles, while 5% were senior managers or specialists. This research was independently conducted for NTT DATA by Jigsaw Research, a global strategic insight agency.
About NTT DATA
NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the leading providers of digital and AI infrastructure in the world. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. Visit us at nttdata.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250617433963/en/
Contacts
Media Contact
Lori Bosio
lori.bosio@nttdata.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom